AI Article Synopsis
- The study focused on breast cancer patients over 65, highlighting their greater risk for side effects from chemotherapy that can lead to early treatment discontinuation, which impacts survival negatively.
- A cohort of 128 women, median age 71, was analyzed for chemotherapy dose changes and side effects, revealing that about 30% faced dose reductions or interruptions.
- Patients who had their chemotherapy altered due to side effects showed worse progression-free survival rates, suggesting that managing side effects is crucial for improving outcomes in this age group.
Article Abstract
Aim: Breast cancer patients over the age of 65 are more likely to suffer chemotherapy side effects, with premature discontinuation, which negatively affects survival.
Methods: We conducted a retrospective cohort study enrolling breast cancer patients; dose reductions or interruptions of chemotherapy have been collected, as well as side effects. Progression-free survival was determined by Kaplan-Meier and evaluated for its association with reduction/suspension. The study included 128 women (median age: 71).
Results: Nineteen patients experienced cardiotoxicity, while dosage of chemotherapy was reduced in 23 patients (18.0%), and 14 (10.9%) had premature interruptions. Dose reduction/interruptions were associated with numerically worse progression-free survival (78.2 vs 94.8 months; p = 0.10).
Conclusion: Reduction/discontinuation of chemotherapy due to side effects affected nearly 30% of our population, potentially worsening outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668125 | PMC |
| http://dx.doi.org/10.2144/fsoa-2020-0076 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!